CLOs on the Move

Nobis Rehabilitation Partners

www.nobisrehabpartners.com

 
Nobis Rehabilitation Partners brings together hospitals, developers, and investment partners to develop, operate, and manage inpatient rehabilitation facilities (“IRFs”) throughout the United States. With vast experience developing IRFs across the country, the Nobis team has refined both the physical design and operational functionality of the hospital; ultimately streamlining outcomes and profitability.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Tracey Nixon
Chief Compliance Officer Profile

Similar Companies

Advantia Health

Advantia is transforming healthcare for all women - we`re setting a higher standard of care and convenience while reducing unnecessary costs. Compassion and value inspire everything we do. We take time to listen, answer questions completely, and offer helpful technology between visits so that our patients are empowered and at ease. Alongside coordinated care, Advantia is pioneering care models that align incentives with the best interests of women and their families.

EMQ FamiliesFirst

EMQ FamiliesFirst is a Campbell, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Douglas County Individual Practice Association

Douglas County Individual Practice Association is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Roseburg, OR. To find more information about Douglas County Individual Practice Association, please visit www.dcipa.com

United Network For Organ Sharing

UNOS is the non-profit organization, established in 1984, that maintains the nation's waiting list for deceased organ transplants, under contract with the federal government. It counts all of the nation's organ transplant hospitals and organ donation

StemCells

StemCells, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery primarily in the United States. Its lead therapeutic product candidate, HuCNS-SC cells (purified human neural stem cells), is in development as a potential treatment for a range of central nervous system disorders. The company has conducted a Phase I clinical trial in Pelizaeus-Merzbacher disease, a fatal myelination disorder in children. It is also conducting a Phase I/II clinical trial in chronic spinal cord injury; and has initiated a Phase I/II clinical trial in dry age-related macular degeneration, as well as is pursuing preclinical studies in Alzheimer’s disease. In addition, the company markets a rage of proprietary cell culture products, research grade human cells, and antibody reagents under the SC Proven brand. The proprietary cell culture products include iSTEM, GS1-R, GS2-M, RHB-A, RHB-Basal, NDiff227, NDiff N2, and NDiff N27 supplements, as well as HEScGRO and ESGRO Complete; and antibody reagents comprise STEM24, STEM101, STEM121, and STEM123, which can be used for cell detection, isolation, and characterization. Further, StemCells is involved in developing and commercializing applications of its technologies to enable stem cell-based research. The company sells its tools and technologies products to researchers at academic institutions, pharmaceutical and biotechnology companies, and government laboratories. StemCells, Inc. was founded in 1988 and is headquartered in Newark, California.